DiscoverThe Lancet Rheumatology in conversation withQuirine Dumoulin on the 4-year data from the TREAT-EARLIER trial
Quirine Dumoulin on the 4-year data from the TREAT-EARLIER trial

Quirine Dumoulin on the 4-year data from the TREAT-EARLIER trial

Update: 2024-11-25
Share

Description

Dr Quirine Dumoulin discusses the efficacy of a 1-year course of methotrexate on the development of rheumatoid arthritis in ACPA-negative people with clinically suspect arthralgia and predicted increased risk of rheumatoid arthritis.

Read the full article:
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00196-6?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Quirine Dumoulin on the 4-year data from the TREAT-EARLIER trial

Quirine Dumoulin on the 4-year data from the TREAT-EARLIER trial

The Lancet Group